The oncology focus in drug R&D seen in recent years is resulting in a sustained period of approvals for cancer therapies. This is showing no sign of abating, with 24% (64) drugs currently waiting for approval by the EMA, FDA and PMDA indicated for oncology uses. 50% of these products are in pre-registration for the European market, including Amgen’s bevacizumab and trastuzumab biosimilars, Pfizer’s Besponsa, and Nektar Therapeutics’ Onzeal.

The oncology pipeline is deep in both early and late stage candidates, with developers keen to follow suit after the first wave of immune-oncology approvals. With the cancer market projected to see huge growth in the next decade, we are unlikely to see a reversal of this trend any time soon.